Epidermal growth factor receptor modulation for neural repair: Implications for neurodegenerative disease therapy

Abdulbasit Amin1,2, Marina Badenes3,4

  • 1Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal.

Insights

Epidermal growth factor receptor (EGFR) signaling promotes neural repair but can cause neurotoxicity when dysregulated. Context-dependent EGFR activation offers therapeutic potential for neurodegenerative diseases and neural repair.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) is a key regulator of cell functions, including in the nervous system.
  • EGFR signaling plays context-dependent roles in neural progenitors, astrocytes, and neurons.
  • EGFR activation influences neural regeneration, repair, and potentially neurodegeneration.

Purpose of the Study:

  • To review current knowledge on EGFR signaling in neural repair and neurodegenerative diseases.
  • To discuss the context-dependent roles and therapeutic potential of EGFR modulation.
  • To propose a framework for understanding EGFR as a context-dependent signaling hub.

Main Methods:

  • Literature review of EGFR signaling in neural contexts.
  • Analysis of experimental models of neurodegenerative diseases (Parkinson's, Alzheimer's, MS-like conditions).
  • Synthesis of evidence on EGFR's dual role in neural repair and pathology.

Main Results:

  • Transient EGFR activation supports neural repair (progenitor proliferation, neuronal survival, remyelination).
  • Sustained or excessive EGFR activation drives neuroinflammation, astrogliosis, and neurotoxicity.
  • EGFR modulation shows therapeutic potential in experimental models, though mechanisms require further study.

Conclusions:

  • EGFR acts as a context-dependent signaling hub, with outcomes determined by spatiotemporal regulation.
  • Targeting EGFR offers potential therapeutic strategies for promoting neural repair and mitigating neurodegeneration.
  • Further research is needed to optimize timing, dosing, and safety for EGFR-based therapies.